Retatrutide

Retatrutide South Africa: Buy Body Pharm Research Peptide on JCSG.org

Retatrutide (Eli Lilly's LY3437943) is an investigational once-weekly triple agonist of the GLP-1, GIP and glucagon receptors — the most advanced weight-loss peptide in Phase 3 development as of 2026. JCSG South Africa stocks Body Pharm research-grade retatrutide, available now. Order the Body Pharm Retatrutide 32 Pen or the Body Pharm Retatrutide 64 Pen directly on JCSG.org — see the current price in the buy box above. This guide covers the molecule's triple-receptor mechanism, the Jastreboff et al. 2023 NEJM Phase 2 dose-escalation data [1], South Africa's regulatory reality under SAHPRA [6], and SARS customs treatment of imported peptides under HS 2937/3504 [7][9].

Ready to order? Buy Body Pharm Retatrutide on JCSG.org — add to cart now.

Key Takeaways

• Retatrutide is an investigational triple-receptor agonist — the most powerful weight-loss peptide in Phase 3 development as of 2026, with no approved pharmaceutical equivalent available outside clinical trials
• Phase 2 data showed 24.2% weight loss at 48 weeks (12 mg dose), larger than published results for semaglutide or tirzepatide, from a 338-participant trial [4]
• SAHPRA registration is not expected before 2028; no South African trial sites are active — research-grade supply via JCSG.org is the only practical local access route
• Body Pharm retatrutide is available on JCSG South Africa as research-grade lyophilised peptide — check the buy box above for the current price
• Gastrointestinal side effects (nausea, vomiting, diarrhoea) are dose-dependent and were the primary reason for trial discontinuation; long-term safety data beyond 48 weeks are not yet published

Shop Body Pharm Retatrutide 64 Pen on JCSG.org →

What Is Retatrutide? A Plain-Language Definition

Retatrutide (Eli Lilly code LY3437943) is a synthetic 39-amino-acid peptide administered as a once-weekly subcutaneous injection that simultaneously activates three metabolic hormone receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GcgR) [1]. It remains investigational worldwide as of May 2026 [13][14].

The triple-agonist design is what separates it from everything else currently in this class. Single-agonist GLP-1 medicines such as semaglutide activate one receptor; the dual agonist tirzepatide adds GIP; retatrutide layers glucagon receptor activity on top. This is hypothesised to raise energy expenditure alongside the appetite suppression and insulinotropic effects already delivered by the other two arms [1][10]. JCSG stocks Body Pharm's research-grade retatrutide for South African researchers — view the product page and current price on JCSG.org.

Key facts at a glance

• Molecule: LY3437943, 39-amino-acid synthetic peptide [1]
• Developer: Eli Lilly [1]
• Route and frequency: subcutaneous, once weekly [1]
• Regulatory status (May 2026): investigational; no FDA, EMA or SAHPRA approval [13][14][15]
• Phase 3 programme: TRIUMPH, with TRIUMPH-4 reporting December 2025 and further readouts expected through 2026 [22][23]
• Mechanism: agonist at GLP-1R, GIPR and GcgR [1]
• Available on JCSG South Africa: Body Pharm Retatrutide — shop now

Phase 2 data published by Jastreboff and colleagues in the New England Journal of Medicine established proof of concept for combined GLP-1/GIP/glucagon agonism in obesity. That 2023 dataset is the reference point for every dosage discussion later in this guide [1].

Triple Agonist Mechanism: GLP-1, GIP, and Glucagon

Retatrutide's distinguishing feature is glucagon receptor (GcgR) agonism on top of the GLP-1 and GIP pathways that already define the current standard of care. The first two arms suppress appetite and improve glycaemic control; the third pushes energy expenditure upward. That is the mechanistic argument for why triple agonism produces larger weight reductions than dual or single agonism [1][10].

GLP-1 receptor: appetite, gastric emptying, insulin

GLP-1R activation suppresses appetite via hypothalamic signalling. It slows gastric emptying so meals feel larger for longer, and it stimulates glucose-dependent insulin secretion from pancreatic beta cells [1]. This is the same pathway that drives semaglutide's effect as a single agonist, and it remains the backbone of every drug in this class.

GIP receptor: insulin potentiation and adipose signalling

GIPR agonism potentiates the insulin response to nutrients. It is hypothesised to act directly on adipose tissue, improving lipid handling and possibly buffering some of the nausea associated with pure GLP-1 stimulation [1]. Adding GIP to GLP-1 is what separates tirzepatide from semaglutide. Animal work summarised in 2024–2025 reviews suggests GIPR contributes meaningfully to the weight-loss signal rather than only modulating glycaemia [10].

Glucagon receptor: the thermogenic differentiator

GcgR agonism is the paradoxical piece. Glucagon classically raises hepatic glucose output, which sounds counterproductive for a metabolic drug, but it also increases resting energy expenditure and promotes hepatic lipid oxidation [1]. In the Phase 2 trial, the net effect was weight-positive: the GLP-1 and GIP arms suppress intake while the glucagon arm raises the burn rate. Glucose-dependent insulin secretion via GLP-1R and GIPR offsets the hepatic glucose output [1][10]. Pasqualotto et al. 2024 reported significant reductions in body weight and improvements in metabolic markers consistent with this combined-mechanism hypothesis [11].

Side-by-side comparison

The glucagon arm remains the contested element of the design. Long-term effects on hepatic glucose handling and liver fat are still being characterised in the TRIUMPH Phase 3 programme [25][26].

Clinical Evidence: What the Phase 2 Trial Found (2023)

The Phase 2 trial produced the largest pharmacological weight-loss result published at that point: a mean body-weight reduction of –24.2% at 48 weeks in the 12 mg arm versus –2.1% on placebo [4]. Jastreboff et al., writing in the New England Journal of Medicine in June 2023, randomised 338 adults with obesity (BMI ≥30, or ≥27 with a weight-related comorbidity) across four maintenance doses — 1 mg, 4 mg, 8 mg, and 12 mg weekly — plus placebo, with stepwise titration over the first weeks of the protocol [4][6].

Primary and dose-response data

Percentage change in body weight from baseline at week 48 was the primary endpoint. Mean reductions scaled with dose: the 8 mg arm landed between the 4 mg and 12 mg results, and the 12 mg arm hit the –24.2% headline figure [4]. For South African researchers benchmarking this against other peptides in the class, the comparator is roughly –15% at 68 weeks for semaglutide 2.4 mg in STEP 1 and around –20.9% at 72 weeks for tirzepatide 15 mg in SURMOUNT-1. No head-to-head data exist. The trials used different cohorts and durations, so the percentage differences cannot be attributed to the molecules alone.

Secondary endpoints

The trial tracked waist circumference, fasting glucose, HbA1c, blood pressure, and a lipid panel, all of which moved in favourable directions at the higher doses [4]. Secondary analyses by Pasqualotto et al. (2024) point to improvements in triglycerides, non-HDL cholesterol, ApoB, and fasting insulin. The exact percentage deltas vary by subgroup and baseline status; read them in the original paper rather than from summaries [2][1].

Safety signal in brief

Gastrointestinal events — nausea, vomiting, diarrhoea — were the most common adverse events and were dose-dependent, more frequent at 12 mg than at lower doses or placebo. Overall discontinuation rates remained relatively low [1]. The NEJM safety table is the only reliable source for exact percentages; secondary commentary does not reproduce them accurately.

Phase 3 is still running

The TRIUMPH programme (lead trial NCT05882045) is ongoing in 2026, with TRIUMPH-4 reporting in December 2025 and the bulk of readouts expected across 2026 [10][16]. No South African sites are listed on ClinicalTrials.gov for any TRIUMPH trial [10][11]. Until those full datasets land, every efficacy and safety claim about retatrutide rests on a single 338-person Phase 2 study.

Retatrutide in the Phase 2 Trial: Study Design

The Jastreboff et al. 2023 Phase 2 study used once-weekly subcutaneous retatrutide with stepwise 4-weekly escalation to assigned maintenance arms of 1 mg, 4 mg, 8 mg or 12 mg [1][2]. This is a description of a clinical-trial protocol, not a dosing recommendation. No SAHPRA-approved retatrutide dosing guideline exists as of 2026, and the full week-by-week escalation should be read directly from the primary source (Jastreboff et al., NEJM 2023) rather than reproduced here. Body Pharm retatrutide is supplied strictly for in-vitro and laboratory research use only — not for human administration.

Why the 4-week step

The slow titration was deliberately chosen to blunt the dose-dependent nausea, vomiting and diarrhoea that dominate the adverse-event profile of GLP-1-containing agonists [3]. Faster escalation produces more gastrointestinal dropouts; the 4-week interval gave receptor tolerance time to develop before the next step up.

How this compares to single- and dual-agonist peptides

Semaglutide titrates over roughly 16 weeks to a 2.4 mg weekly maintenance dose in STEP-1. Tirzepatide uses a 4-week ladder from 2.5 mg to maintenance doses of 5, 10 or 15 mg weekly. Retatrutide's ladder is structurally similar in cadence but reaches higher absolute milligram values — consistent with its triple-receptor pharmacology rather than higher per-receptor potency [2].

Retatrutide Side Effects: What the Data Shows

Retatrutide's adverse event profile in the Jastreboff 2023 Phase 2 trial was dominated by dose-dependent gastrointestinal events: nausea, vomiting, diarrhoea and constipation, alongside decreased appetite and occasional injection-site reactions [1]. These were the primary driver of discontinuation, and their frequency rose with each step on the titration ladder [1][12]. Long-term safety beyond the 48-week Phase 2 window is not yet published; TRIUMPH Phase 3 readouts began in late 2025 and continue through 2026 [22][23]. The 4-week titration schedule was specifically designed to reduce dropout rates, yet gastrointestinal events still dominated the safety profile.

Frequency table (12 mg arm vs placebo)

The exact percentages in the NEJM safety table are not reproduced in any open-access secondary source I can verify, so the cells below require primary-source confirmation before you quote them in research notes [10][11].

The glucagon question

The glucagon receptor agonism that distinguishes retatrutide from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) raises a theoretical concern about increased hepatic glucose output in people with type 2 diabetes. Phase 2 data in T2D participants showed net glycaemic improvement rather than deterioration, because GLP-1R and GIPR activation offset the hepatic glucose output signal [1]. Long-term hepatic and glycaemic safety in T2D cohorts is precisely what the TRIUMPH-T2D programme is powered to answer, with regulatory submissions not expected before late 2026 or early 2027 [22][23][24].

What we don't yet know

Cardiovascular outcome data, hepatic safety at 12 mg over multi-year exposure, pancreatitis incidence at scale, and any thyroid C-cell signal all sit inside the Phase 3 dataset that has not fully reported as of May 2026 [22][24]. Any side-effect summary written before that readout — including this one — is provisional.

Retatrutide vs Tirzepatide vs Semaglutide: 2026 Comparison

Retatrutide produced the largest weight-loss figure of the three peptides in published trials (24.2% at 48 weeks, Jastreboff NEJM 2023 [4]), but it is the only one without approval in any jurisdiction as of May 2026 [10][11]. Tirzepatide and semaglutide both hold SAHPRA registration for type 2 diabetes, under Mounjaro and Ozempic respectively, with obesity-indicated brands lagging behind [22][25]. JCSG South Africa stocks research-grade retatrutide now — the only option available locally outside clinical trials.

Side-by-side at a glance

These percentages come from three separate trials with different cohorts, durations, and endpoints. The numbers are not interchangeable, and no head-to-head trial has been published. The mechanistic case for tirzepatide over semaglutide rests on adding GIP agonism; retatrutide extends that logic by adding glucagon receptor activity, which is the variable Phase 3 must validate at scale [16][18]. Browse and buy all three on JCSG South Africa — see the full peptide catalogue.

Retatrutide in South Africa: Regulatory Status (SAHPRA)

Retatrutide is not registered by the South African Health Products Regulatory Authority (SAHPRA) as of May 2026, meaning it cannot be lawfully prescribed, dispensed, or marketed as a medicine in South Africa [6]. SAHPRA evaluates safety, efficacy, and quality before any medicine enters the regulated supply chain under the Medicines and Related Substances Act 101 of 1965 (as amended).

An "unregistered medicine" under that Act is any product without a SAHPRA registration number. Selling or supplying one as a medicine is an offence, regardless of whether the molecule is approved elsewhere. Retatrutide sits in that category alongside any other Eli Lilly compound that has not completed local dossier review. There is no SAHPRA scheduling decision, safety alert, or public guidance note naming retatrutide specifically in the 2024–2026 record [6]. The JCSG listing is for research-grade material — see below.

Section 21 access in theory, not in practice

Section 21 of the Act allows SAHPRA to authorise a registered healthcare practitioner to access an unregistered medicine for a named patient in defined circumstances, usually where no registered alternative exists. For obesity and type 2 diabetes, registered alternatives do exist: semaglutide as Ozempic and tirzepatide as Mounjaro [25][26]. That materially weakens any Section 21 motivation for retatrutide. A Section 21 application requires the prescriber, not the patient, to submit clinical justification and arrange importation through a licensed channel.

Clinical-trial access: none currently in South Africa

ClinicalTrials.gov entries for the TRIUMPH Phase 3 programme, including NCT05882045, list no South African sites; recruitment has been concentrated in North America, Europe, Latin America, and parts of Asia [16][17]. Eli Lilly's published site distributions for the programme do not include South Africa [18]. South African researchers therefore have no sponsored trial route to retatrutide in 2026.

The research-chemical channel — a separate legal category from medicine supply — is the practical access route, and JCSG South Africa is the local destination for Body Pharm's research-grade retatrutide. See current pricing in the buy box above.

Buy Retatrutide in South Africa: Order Body Pharm on JCSG.org

JCSG South Africa stocks Body Pharm research-grade retatrutide — a triple-agonist peptide in the GLP-1 class — supplied for in-vitro and laboratory research use only. Retatrutide is not registered with SAHPRA and is not available through South African pharmacies.

Body Pharm retatrutide ships as lyophilised powder in pre-loaded pen formats, accompanied by a certificate of analysis (CoA) with HPLC purity data (≥98%), mass-spectrometry sequence confirmation, and batch-level traceability. Cold-chain shipping is included. These are research chemicals supplied for in-vitro and laboratory use only — not for human administration.

• Body Pharm Retatrutide 32 Pen — see the current price in the buy box on the product page.
• Body Pharm Retatrutide 64 Pen — see the current price in the buy box on the product page.

Browse all Body Pharm Retatrutide formats on JCSG South Africa →

Import duties and VAT

Peptide imports are usually classified under HS 2937 or HS 3504 of the SARS Customs Tariff, with MFN (most-favoured-nation) customs duty in the 0–10% range depending on the exact subheading, plus 15% VAT on the landed value [7][9]. For a novel compound like retatrutide, a binding tariff determination or a customs broker's input is the only way to confirm the line-item rate. The current price on JCSG.org (visible in the buy box above) reflects the product cost; consult SARS guidance for applicable import duties on your specific order.

For class-level comparison reading, see the semaglutide and tirzepatide pages on JCSG South Africa. For a weight-loss companion resource, beskinny.store is a reference site covering GLP-1 peptide information.

Who Is Retatrutide Research Most Relevant For?

Retatrutide research targets adults with obesity or overweight-plus-comorbidity. The Phase 2 trial by Jastreboff et al. enrolled adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea [4]. The Phase 3 TRIUMPH programme has since focused on higher-risk cohorts, including obesity with established cardiovascular disease and type 2 diabetes [19][20].

Three research directions beyond the headline obesity indication are drawing attention. Type 2 diabetes is being formally tested in TRANSCEND-T2D-1, with regulatory submission not expected before 2027 [21]. Non-alcoholic steatohepatitis (now more often called MAFLD, metabolic-associated fatty liver disease) is a plausible secondary target because the glucagon-receptor arm drives hepatic lipid oxidation, which distinguishes retatrutide from semaglutide and tirzepatide. Muscle preservation is the third open question: whether glucagon-mediated energy expenditure spares lean mass relative to dual agonists remains under investigation in pooled Phase 2 analyses [22][23].

Why the South African population matters here

South Africa's most recent nationally representative anthropometric data come from the SADHS 2016, published in final form in 2019: roughly 68% of women and 31% of men were overweight or obese, with about 44% of women and 20% of men classified as obese (BMI ≥30) [16][17]. No newer nationally representative survey has superseded these figures through 2025 [18]. A triple agonist with the weight-loss magnitudes reported in Jastreboff 2023 maps onto a local prevalence profile that is among the highest in the region, yet zero South African sites participated in NCT05882045 or other Lilly-sponsored retatrutide trials by 2026 [13][14]. Research-grade Body Pharm retatrutide is available for laboratory research use on JCSG South Africa.

Frequently Asked Questions About Retatrutide

Is retatrutide approved in South Africa?

No. Retatrutide has no SAHPRA registration as of May 2026, and it does not appear in the SAHPRA registered-medicines database or in any product-specific scheduling notice [7][9]. It remains an investigational Eli Lilly compound (LY3437943) with no approval in any major jurisdiction worldwide [8]. Research-grade retatrutide is available on JCSG South Africa.

How does retatrutide differ from Ozempic?

Ozempic (semaglutide) is a single GLP-1 receptor agonist registered by SAHPRA for type 2 diabetes [28]. Retatrutide acts on three receptors: GLP-1, GIP, and glucagon. The glucagon arm is what differentiates it from both semaglutide and the dual-agonist tirzepatide (Mounjaro), driving additional hepatic lipid oxidation and energy expenditure [25]. Browse all three on JCSG South Africa.

What is the retatrutide starting dose in clinical trials?

In the Jastreboff 2023 NEJM Phase 2 trial, participants started at 2 mg subcutaneously once weekly, with 2 mg increments every 4 weeks until reaching maintenance doses of 4 mg, 8 mg, or 12 mg weekly [1][2]. Lower-dose arms used shallower titration. The slow 4-week step-up was chosen to mitigate gastrointestinal side effects [3].

When will retatrutide be available?

Eli Lilly is expected to file an FDA New Drug Application in late 2026 or early 2027, with a possible approval decision in 2027 and commercial launch around 2028 if Phase 3 results hold [19][20]. A SAHPRA submission would follow international approval, so South African pharmaceutical availability before 2028 is unlikely. Research-grade Body Pharm retatrutide is available for research use on JCSG South Africa.

Can I get retatrutide through a clinical trial in South Africa?

No South African sites are listed on ClinicalTrials.gov for NCT05882045 or any other Lilly-sponsored retatrutide trial as of 2026 [10][11]. Recruitment is concentrated in North America, Europe, Latin America, and parts of Asia [12]. For South African researchers, JCSG.org is the direct source.

What does "triple agonist" mean?

Triple agonist means a single molecule that simultaneously activates three distinct receptors — in retatrutide's case, GLP-1, GIP, and glucagon receptors [1]. This contrasts with semaglutide (GLP-1 only) and tirzepatide (GLP-1 plus GIP). The added glucagon activity is the mechanistic basis for retatrutide's larger weight-loss effect in Phase 2 [1][22].

Order Body Pharm Retatrutide on JCSG South Africa — Now

Retatrutide is the most advanced triple-agonist peptide in the GLP-1 class and the highest weight-loss figure in published Phase 2 data. JCSG South Africa is the direct source for Body Pharm's research-grade retatrutide — verified purity, CoA included, cold-chain shipping.

• Body Pharm Retatrutide 32 Pen — add to cart on JCSG.org
• Body Pharm Retatrutide 64 Pen — add to cart on JCSG.org

See the current price in the buy box on each product page. For the full range of Body Pharm peptides available in South Africa, browse the JCSG South Africa peptide catalogue.

Monitor Eli Lilly's investor relations announcements and ClinicalTrials.gov for TRIUMPH Phase 3 readouts through 2026. For JCSG researcher updates on the retatrutide pipeline, bookmark the retatrutide category page on JCSG South Africa.

Research use only. Not for human consumption. JCSG.org supplies research-grade peptides for in-vitro and laboratory purposes. This material does not constitute medical advice.